# EDGAR Filing Document

**Accession Number:** 0001865494
**File Stem:** 0001193125-25-137907
**Filing Date:** 2025-6
**Character Count:** 2389
**Document Hash:** 675d7c24e61de3e4103598a534ef18c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-137907.hdr.sgml**: 20250711

**ACCESSION NUMBER**: 0001193125-25-137907

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IO Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001865494
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870909276
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** OLE MAALOES VEH 3
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 2200
- **BUSINESS PHONE:** 4570702980

**MAIL ADDRESS:**
- **STREET 1:** OLE MAALOES VEH 3
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 2200

**IO Biotech, Inc.** 

**Ole Maaløes Vej 3** 

**DK-2200 Copenhagen N** 

**Denmark** 

June 9, 2025

<u>Via EDGAR</u> 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Tim Buchmiller

Re: IO Biotech, Inc.

Registration Statement on Form S-3, as amended

File No. 333-287554

**Acceleration Request**

**Requested Date: June 11, 2025**

**Requested Time: 4:00 P.M., Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, IO Biotech, Inc. (the "***Company***") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3, as amended (the "***Registration Statement***"), be accelerated so that the Registration Statement will become effective at 4:00 P.M., Eastern Time, on June 11, 2025, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

Please contact Nick DeAngelis of Sidley Austin LLP at (214) 969-3563 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.

---

| |
|:---|
| Very truly yours, |
| /s/ Devin Smith |
| Devin Smith |
| General Counsel |
| IO Biotech, Inc. |

---

cc: Mai-Britt Zocca, IO Biotech, Inc.

Amy Sullivan, IO Biotech, Inc.

Frank Rahmani, Sidley Austin LLP

Istvan Hajdu, Sidley Austin LLP

Nick DeAngelis, Sidley Austin LLP